Rosanna Squitti

Dr. Rosanna Squitti

Dipartimento di Medicina di Laboratorio, Sezione Ricerca e Sviluppo, Ospedale Generale,‘San Giovanni Calibita’ FATEBENEFRATELLI, Isola Tiberina -00186 Roma, Italy
orcid

Research Focus & Metrics

Academic Career Length

33Years (1994-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2013 in Neurobiology of Disease
Verified
Journal Article
Closed access
MSMatthew Schrag
Matthew Schrag
CMC. Mueller
C. Mueller
MZM. Zabel
M. Zabel
ACA. Crofton
A. Crofton
WKW.M. Kirsch
W.M. Kirsch
George PerryGeorge Perry
George Perry

1 September 2014 in Neurobiology of Aging
Verified
Journal Article
Open access
NBNeal Barnard
Neal Barnard
Ashley I. BushAshley I. Bush
Ashley I. Bush
ACAntonia Ceccarelli
Antonia Ceccarelli
JCJames Cooper
James Cooper
CJCeleste A. de Jager
Celeste A. de Jager
Rosanna SquittiRosanna Squitti
Rosanna Squitti
Risk of developing Alzheimer's disease is increased by older age, genetic factors, and several medical risk factors. Studies have also suggested that dietary and lifestyle factors may influence risk, raising the possibility that preventive strategies may be effective. This body of research is incomplete. However, because the most scientifically supported lifestyle factors for Alzheimer's disease are known factors for cardiovascular diseases and diabetes, it is reasonable to provide preliminary guidance to help individuals who wish to reduce their risk. At the International Conference on Nutrition and the Brain, Washington, DC, July 19-20, 2013, speakers were asked to comment on possible guidelines for Alzheimer's disease prevention, with an aim of developing a set of practical, albeit preliminary, steps to be recommended to members of the public. From this discussion, 7 guidelines emerged related to healthful diet and exercise habits.

1 December 2018 in Trends in Pharmacological Sciences
Verified
Journal Article
Closed access
SSStefano L. Sensi
Stefano L. Sensi
AGAlberto Granzotto
Alberto Granzotto
MSMariacristina Siotto
Mariacristina Siotto
Rosanna SquittiRosanna Squitti
Rosanna Squitti

23 January 2018 in Frontiers in Aging Neuroscience
Verified
Journal Article
Open access
PDF file
SBSoghra Bagheri
Soghra Bagheri
Rosanna SquittiRosanna Squitti
Rosanna Squitti
THThomas Haertlé
Thomas Haertlé
Mariacristina SiottoMariacristina Siotto
Mariacristina Siotto
ASAli Akbar Saboury
Ali Akbar Saboury
Alzheimer’s disease (AD) is a neurodegenerative disorder that is characterized by amyloid plaques in patients’ brain tissue. The plaques are mainly made of β-amyloid peptides and trace elements including Zn2+, Cu2+, and Fe2+. Some studies have shown that AD can be considered a type of metal dyshomeostasis. Among metal ions involved in plaques, numerous studies have focused on copper ions, which seem to be one of the main cationic elements in plaque formation. The involvement of copper in AD is controversial, as some studies show a copper deficiency in AD, and consequently a need to enhance copper levels, while other data point to copper overload and therefore a need to reduce copper levels. In this paper, the role of copper ions in AD and some contradictory reports are reviewed and discussed.

22 October 2002 in Neurology
Verified
Journal Article
Closed access
PDF file
Rosanna SquittiRosanna Squitti
Rosanna Squitti
DLD. Lupoi
D. Lupoi
PPP. Pasqualetti
P. Pasqualetti
GFG. Dal Forno
G. Dal Forno
FVF. Vernieri
F. Vernieri
PRP. M. Rossini
P. M. Rossini
Objective: To determine whether serum trace metals and oxidative species are related to abnormal cognition in AD. Methods: The authors studied serum peroxides, copper, iron, transferrin, and antioxidant capacity in 79 patients with AD (mean age 74.3 years; 25 men, 54 women) and in 76 cognitively normal individuals (mean age 70.1 years; 33 men, 43 women). The relation of these oxidative and trace metals to APOE ε4 allele frequency, neuropsychological performance, and cerebrovascular or atrophic burden, as estimated by brain MRI and ultrasonography of cerebral vessels, was evaluated. Results: Copper level was higher (p < 0.001) in subjects with AD than control subjects (specificity = 95%, sensitivity = 60%) with a cutoff serum level of 16 μmol/L (1.02 mg/L). An increase of 1 μmol/L in serum copper accounted for 80% of the risk of having AD and correlated with poor neuropsychological performance and medial temporal lobe atrophy (p < 0.03). Antioxidant capacity decreased and correlated with medial temporal lobe atrophy (p < 0.009) and with APOE ε4 allele (p = 0.004). Conclusions: Copper may play a role in neurodegenerative processes in AD, and serum copper measurement may prove to be a peripheral diagnostic marker for AD.

11 July 2006 in Neurology
Verified
Journal Article
Closed access
PDF file
Rosanna SquittiRosanna Squitti
Rosanna Squitti
GBGiulia Barbati
Giulia Barbati
LRL. Rossi
L. Rossi
MVM. Ventriglia
M. Ventriglia
GFG. Dal Forno
G. Dal Forno
PRP. M. Rossini
P. M. Rossini
Objective: To assess whether serum copper in Alzheimer disease (AD) correlates with cognitive scores, β-amyloid, and other CSF markers of neurodegeneration.